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Abstract
Background—In 2007, 29% of HIV-infected Kenyans in need of antiretroviral therapy (ART), 
based on an immunologic criterion of CD4 ≤350 cells per microliter, were receiving ART. Since 
then, substantial treatment scale-up has occurred in the country. We analyzed data from the second 
Kenya AIDS Indicator Survey (KAIS 2012) to assess progress of treatment scale-up in Kenya.
Methods—KAIS 2012 was a nationally representative survey of persons aged 18 months to 64 
years that collected information on HIV status, care, and treatment. ART eligibility was defined 
based on 2 standards: (1) 2011 Kenya eligibility criteria for ART initiation: CD4 ≤350 cells per 
microliter or co-infection with active tuberculosis and (2) 2013 World Health Organization 
(WHO) eligibility criteria for ART initiation: CD4 ≤500 cells per microliter, co-infection with 
active tuberculosis, currently pregnant or breastfeeding, and infected partners in serodiscordant 
relationships. Blood specimens were tested for HIV antibodies and HIV-positive specimens tested 
for CD4 cell counts.
Results—Among 13,720 adults and adolescents aged 15–64 years, 11,626 provided a blood 
sample, and 648 were HIV infected. Overall, 58.8% [95% confidence interval (CI): 52.0 to 65.5) 
were eligible for treatment using the 2011 Kenya eligibility criteria and 77.4% (95% CI: 72.4 to 
82.4) using the 2013 WHO eligibility criteria. Coverage of ART was 60.5% (95% CI: 50.8 to 
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70.2) using the 2011 Kenya eligibility criteria and 45.9% (95% CI: 37.7 to 54.2) using the 2013 
WHO eligibility criteria.
Conclusions—ART coverage has increased from 29% in 2007 to 61% in 2012. If Kenya adopts 
the 2013 WHO guidelines for ART initiation, need for ART increases by an additional 19 
percentage points and current coverage decreases by an additional 15 percentage points, 
representing an additional 214,000 persons who will need to be reached.
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INTRODUCTION
By the end of 2011, an estimated 34 million people were living with HIV infection 
worldwide, the majority of whom resided in sub-Saharan Africa.1 Antiretroviral therapy 
(ART) reduces morbidity, mortality, and sexual transmission of HIV.2–6 Although 
international donors have made funds available for ART in sub-Saharan Africa, 
approximately half of persons eligible for HIV treatment were not receiving ART.1 In 
Kenya, there were an estimated 1.2 million adults living with HIV as of the end of 2012.7 In 
2007, 40.5% of HIV-infected persons aged 15–64 years who met the immunologic criterion 
for initiating ART at that time (CD4 ≤250 cells/μL) were receiving treatment.8 In 2011, 
Kenya adopted a higher immunologic threshold to determine eligibility for ART (CD4 ≤350 
cells/μL). Based on this updated threshold, 28.6% of persons eligible for ART were 
receiving treatment in 2007.8,9
In response to the growing need for HIV testing and treatment, Kenya developed a national 
HIV/AIDS strategic plan that aims to reduce HIV transmission, morbidity, and mortality in 
part through increasing the number of treatment-eligible persons receiving ART.10 Efforts to 
expand HIV testing have resulted in a substantial increase in the percentage of Kenyan 
adults and adolescents who have ever been tested, from 36.6% in 2007 to 70.1% in 2012.11 
Subsequently, the number of adults who have received ART has increased almost 3-fold 
during the same period, from 184,000 in 2007 to 525,000 by year-end 2012.12 In 2013, the 
World Health Organization (WHO) released new guidance on the use of ART to treat and 
prevent HIV infection.13 This guidance recommends raising the immunologic threshold for 
ART initiation from CD4 ≤350 cells per microliter to CD4 ≤500 cells per microliter and, in 
addition to the 2011 Kenyan eligibility criteria for ART initiation, recommends ART for 
HIV-infected women who are pregnant or breastfeeding and HIV-infected persons in 
serodiscordant relationships, irrespective of CD4 cell count. Kenya plans to integrate these 
new criteria in its next national strategic plan for HIV care and treatment in 2014. Although 
not currently eligible for treatment under the Kenya or WHO guidance, it is anticipated that 
persons with CD4 >500 cells per microliter will ultimately require treatment in the future.
The second Kenya AIDS Indicator Survey (KAIS 2012) was a nationally representative 
survey of adults and children aged 18 months to 64 years residing in Kenya that collected 
information on HIV diagnosis, care, and treatment and tested participants for HIV antibodies 
and CD4 cell counts. We used data from HIV-infected adults and adolescents aged 15–64 
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years to estimate the need for ART and coverage of ART using different eligibility criteria 
for ART initiation.
METHODS
Study Design and Population
The methods used in KAIS 2012 have been previously described.14 Briefly, a cross-
sectional household survey of adults and children aged 18 months to 64 years was conducted 
from October 2012 to February 2013 using a stratified 2-stage cluster sample to identify 
households and within households, eligible residents. The North Eastern region was not 
surveyed because of regional insecurity. This analysis was restricted to subjects aged 15–64 
years with a confirmed HIV-positive test result from central laboratory testing in Nairobi.
Data Collection Methods
Participants were interviewed face-to-face regarding household and demographic 
characteristics, HIV testing history, and use of HIV-related care for persons known to be 
HIV infected. Information was collected on tablet computers (Mirus Innovations, 
Mississauga, Ontario, Canada) and transmitted electronically to a central database in 
Nairobi. Blood was obtained and tested at the National HIV Reference Laboratory for HIV 
antibodies using the Vironostika HIV-1/2 UNIF II Plus O Enzyme Immunoassay 
(bioMérieux, Marcy d’Etoile, France) as the screening assay and the Murex HIV.1.2.O HIV 
Enzyme Immunoassay (DiaSorin, SpA, Sal-uggia, Italy) as the confirmatory assay. HIV-
positive specimens were further tested for CD4 cell count using the BD FACSCalibur flow 
cytometer (Becton Dickinson BioSciences, San Jose, CA). Due to hemolysis, 54.0% of HIV-
positive specimens were not available for CD4 cell count testing at the National HIV 
Reference Laboratory.
Measures
We used self-reported data from the interview to determine each HIV-infected participant’s 
knowledge of his or her HIV infection, current HIV care clinic attendance (defined as 
having attended the clinic in the past six months), current treatment for tuberculosis co-
infection, and current ART usage. We classified participants into 4 categories: (1) those who 
were unaware of their HIV infection (ie, self-reported being HIV uninfected or not having 
been previously tested); (2) those who were aware of their infection (ie, self-reported being 
diagnosed before the survey), currently receiving care, and currently receiving ART; (3) 
those who were aware of their infection and currently receiving care but not currently 
receiving ART; and (4) those who were aware of their infection but not currently receiving 
care or ART. Participants who reported that they were not currently attending an HIV care 
clinic but were currently receiving ART were classified as currently receiving care and 
ART.
We measured eligibility for ART using 2 eligibility standards: (1) the 2011 Kenya eligibility 
criteria for ART initiation and (2) the 2013 WHO eligibility criteria for ART initiation. The 
Kenya criteria were based on the 2011 National Guidelines for ART, which recommend 
treatment for persons with CD4 ≤350 cells per microliter or, irrespective of CD4 cell count, 
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persons with active tuberculosis co-infection and persons with chronic Hepatitis B virus co-
infection requiring therapy.9 The WHO criteria were based on the 2013 WHO 
recommendations on priority populations to initiate ART, including persons with CD4 ≤500 
cells per microliter, or irrespective of CD4 cell count, persons with active tuberculosis co-
infection, persons with chronic Hepatitis B virus co-infection requiring therapy, women who 
were pregnant or breastfeeding, and partners of HIV-infected partners in serodiscordant 
relationships.13 We used self-reported data on current treatment for tuberculosis as a proxy 
for active co-infection with tuberculosis. Because persons who were currently receiving 
ART will continue to need ART in the future, they were included in denominator for 
determining need for ART. Clinical staging information and Hepatitis B virus status were 
not collected in KAIS 2012 and therefore were not used for determining eligibility.
Analysis
All analyses were performed in SAS version 9.3 (SAS Institute Inc., Cary, NC) using the 
SURVEYFREQ procedure to take into account the stratified cluster design of the survey. 
Estimates were weighted to account for sampling probability and adjust for nonresponse. 
Statistical significance for cross-tabulations was assessed using the Rao-Scott χ2 test. To 
estimate the number of adults and adolescents living with HIV, we applied non-normalized 
survey weights to the outcome variable of HIV infection and rounded estimates to the 
nearest 1000. Non-normalized weights were based on the 2012 projected population data in 
the 2009 Kenya Population and Housing Census15 and adjusted for missing CD4 results 
when CD4 testing was not performed.
ART need and coverage were calculated using the 2011 Kenya eligibility criteria for ART 
initiation and the 2013 WHO eligibility criteria for ART initiation. We also estimated 
coverage assuming that all infected persons were in need of ART. To determine unmet need 
for ART, we subtracted the number of persons currently receiving ART from the total 
number of persons eligible for ART. Population estimates for eligibility, coverage, and 
unmet need were calculated by multiplying each stratum with the estimated number of 
adults and adolescents living with HIV. For population estimates, we excluded respondents 
whose eligibility could not be classified because a CD4 cell count test was not conducted.
Ethical Considerations
This study was approved by the Kenya Medical Research Institute’s Ethical Review 
Committee, the US Centers for Disease Control and Prevention’s Institutional Review 
Board, and the Committee on Human Research of the University of California, San 
Francisco.
RESULTS
We surveyed 13,720 participants and collected blood specimens from 11,626 (84.7%). Of 
these, 648 (5.6%) were found to be HIV infected. A greater proportion of HIV infections 
were observed in women [62.1%, 95% confidence intervals (CI): 57.7 to 66.5], persons aged 
40 years and above (40.2%, 95% CI: 36.4 to 44.1), persons who had not been educated 
beyond primary school (45.6%, 95% CI: 40.9 to 50.2), and persons who were married of 
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cohabited (61.1%, 95% CI: 56.1 to 66.2) compared to persons of other demographic and 
marital groups (Table 1).
Among HIV-infected participants, 53.1% (95% CI: 47.6 to 58.7) were unaware of their 
infection;11 31.8% (95% CI: 27.1 to 36.5) were aware of their infection, currently in care, 
and receiving ART; 9.9% (95% CI: 7.2 to 12.5) were aware of the infection and currently in 
care but not receiving ART; and 5.2% (95% CI: 3.0 to 7.4) knew they were infected but 
were not currently receiving care (Table 2). There were significant differences in the 
proportions of HIV care and treatment status categories by sex, age, educational attainment, 
and current marital status. The proportion of persons aged 15–19 years who were in care and 
receiving ART (14.1%, 95% CI: 9.1 to 19.0) was low relative to other age groups (30–39 
years: 33.4%, 95% CI: 26.0 to 40.9 and 40 years and above: 43.3%, 95% CI 36.2 to 50.5). 
The proportion of widows in care and receiving ART (49.9%, 95% CI 39.9 to 57.7) was 
higher compared to persons who were married or cohabiting (31.4%, 95% CI: 25.1 to 37.7) 
or in other marital status categories (21.0%, 95% CI: 13.0 to 28.2). There were few 
differences in the demographic characteristic among persons who were not on ART, 
regardless of whether they were in care.
Using the 2011 Kenya eligibility criteria for ART initiation, 58.8% (95% CI: 52.0 to 65.5) or 
an estimated 674,000 (95% CI: 553,000 to 794,000) HIV-infected persons were eligible for 
ART (Table 3). Of those, 60.5% (95% CI: 50.8 to 70.2) or an estimated 407,000 (95% CI: 
312,000 to 503,000) persons were currently receiving ART; 7.0% (95% CI: 2.0 to 12.1) 
were aware of their infection and in care but not receiving ART; 4.1% (95% CI: 0.0 to 8.8) 
were aware of their infection but not in care and not receiving ART; and 28.4% (95% CI: 
19.9 to 36.9) were unaware of their infection and not receiving ART. Therefore, 39.5% of 
persons who were in need of ART, or an estimated 267,000 persons, were not receiving 
treatment. Using the 2013 WHO eligibility criteria for ART initiation, 77.4% (95% CI: 72.4 
to 82.4) or an estimated 880,000 (95% CI: 766,000 to 1,009,000) HIV-infected persons were 
eligible for treatment. Among those eligible for ART, 45.9% (95% CI: 37.7 to 54.2) were 
receiving ART; 10.0% (95% CI: 5.5 to 14.5) were aware of their infection and in care but 
not receiving ART; 4.8% (95% CI: 0.0 to 8.9) were aware of their infection but not in care 
and not receiving ART; and 39.3% (95% CI: 31.7 to 46.9) were unaware of their infection 
and not receiving ART. This corresponds to 54.1% of ART-eligible persons under the 2013 
WHO eligibility criteria, or an estimated 481,000 persons, who were not receiving ART. 
Taking into account the unmet need for ART using the 2011 Kenya eligibility criteria, this 
represents an additional 214,000 persons who will need to be reached under the 2013 WHO 
eligibility criteria for ART initiation.
Assuming universal coverage, all HIV-infected persons would be eligible for ART. Among 
those, 35.5% (95% CI: 28.6 to 42.5) were currently receiving ART; 11.6% (95% CI: 7.4 to 
15.7) were aware of their infection and currently in care but not receiving ART; 5.3% (95% 
CI: 1.9 to 8.8) were aware of their infection but not in care and not receiving ART; and 
47.6% (95% CI: 40.4 to 54.8) were unaware of their infection and not receiving ART. 
Therefore, if all HIV-infected persons were eligible for ART, an additional 473,000 persons 
on top of those already in need for ART under the 2011 Kenya eligibility criteria would 
need to be reached.
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In this nationally representative sample of adults and adolescents aged 15–64 years, we 
estimated that among Kenyans aged 15–64 years who were living with HIV in 2012, 59% 
were eligible for ART, of whom 61% were receiving it. These data represent a major 
milestone in the scale-up of the national ART program over the past 5 years, from an ART 
coverage rate of 29% in 2007 to 61% in 2012 among treatment-eligible persons.8
By year-end 2012, routinely collected service delivery data from health facilities indicated 
that approximately 525,000 Kenyan adults were receiving ART.12 Although our population 
estimate of ART coverage in KAIS 2012 was lower, the upper bound of our estimate (ie, 
503,000 persons) fell within range of the programmatic estimate. We also expect our 
estimates of ART coverage in a national household survey to be an underestimate of the true 
value in the population, given the likely impact of social desirability bias on the accuracy of 
self-reported responses for sensitive questions, such as HIV status and HIV care and 
treatment experience.
As Kenya moves towards adopting the 2013 WHO guidance for initiating ART, the need for 
ART will increase by an additional 19 percentage points and current coverage will decrease 
by an additional 15 percentage points, representing approximately 214,000 additional 
persons who will need to be reached beyond current need. Although these numbers reflect 
anticipated treatment needs in Kenya, ultimately all currently infected persons and persons 
who later acquire infection will likely need to receive lifelong treatment. Funding treatment 
in the context of diminishing donor funds presents a challenge for Kenya.16
Despite progress in treatment scale-up, more than 50% of HIV-infected adults and 
adolescents were unaware of their infection, and that a greater proportion of men than 
women were unaware of their infection.11 Given that the majority of infections are 
transmitted from persons who are unaware of their infection, in the absence of marked 
increases in HIV diagnosis and treatment to maintain viral suppression, Kenya will face 
substantial ongoing HIV transmission.17,18
Although these findings are concerning, the fact that the proportion of persons who are 
aware of their infection has increased substantially since 2007 suggests that efforts to 
expand HIV testing through provider-initiated and home-based testing and counseling are 
making a difference.11 The lower proportion of women who were unaware of their infection 
is likely due to the success of opt-out testing provided through the prevention of mother-to-
child transmission of HIV programs where rates of test acceptance are very high.19
We found that a high proportion of diagnosed persons were receiving care and that 7% of 
persons in care who met the Kenya eligibility criteria for initiating ART were not receiving 
ART. Although the proportion may seem relatively low, this represents an estimated 47,000 
persons in care who require ART. This gap may be due, at least in part, to prioritization of 
health care services for persons receiving treatment over the pre-ART population in 
care.20–24
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There are important limitations to consider when interpreting the results of this analysis. 
Security concerns resulted in not sampling the North Eastern region, and our findings may 
not be completely representative of the entire country. However, in KAIS 2007, the North 
Eastern region had the lowest HIV prevalence (0.8%) and lowest number of survey 
participants (2% of total national sample) compared to other regions.8 Therefore, exclusion 
of this region in KAIS 2012 did not substantially impact the generalizability of these results 
for the country. Hemolysis of transported blood specimens resulted in the loss of 54% of 
HIV-positive samples eligible for CD4 testing. There were no differences in sex, age, 
residence, and geographic region between HIV-infected persons with and without CD4 test 
results; therefore, we believe that any bias from this loss to be minimal. Our study relied on 
self-report of HIV infection and use of HIV care and treatment services. Concern over 
disclosure of HIV status may have over-estimated the proportion of persons with 
undiagnosed HIV infection, leading to underreporting of previously received treatment and 
care services, resulting in underestimation of ART coverage in our study. Finally, we had no 
objective measures of clinical indicators for ART and Hepatitis B virus infection and for this 
reason relied only on immunologic criterion and self-reported data on current treatment for 
tuberculosis disease, current pregnancy, and current breastfeeding status to determine need 
for ART. As such, our estimates of treatment-eligible persons may be underestimated.
Despite these limitations, as a national population-based survey, our study is reasonably 
representative and provides data not available elsewhere with which we were able to obtain 
estimates of coverage and unmet need for treatment. Efforts to increase the proportion of 
infected persons who are aware of their infection is critical because knowledge of one’s 
infection leads to reduced risk behavior, provides the opportunity to identify additional 
infections by disclosing infection status to partners, and is the first step in accessing ART. 
Once in care, more infected persons must initiate and sustain ART to reduce HIV 
transmission. Our conservative estimate of the number of persons in need of treatment 
should be used to obtain direct resources for ART clinics and support services to maximize 
retention and compliance with care and treatment. Finally, continued monitoring of HIV 
prevalence, testing, care use, and care outcomes is needed to evaluate the success of 
expanded efforts and to determine future needs.
Acknowledgments
KAIS 2012 was supported by the National AIDS and STI Control Programme (NASCOP), Kenya National Bureau 
of Statistics (KNBS), National Public Health Laboratory Services (NPHLS), National AIDS Control Council 
(NACC), National Council for Population and Development (NCPD), Kenya Medical Research Institute (KEMRI), 
US Centers for Disease Control and Prevention (CDC/Kenya, CDC/Atlanta), United States Agency for 
International Development (USAID/Kenya), University of California, San Francisco (UCSF), Joint United Nations 
Team on HIV/AIDS, Japan International Cooperation Agency (JICA), Elizabeth Glaser Pediatric AIDS Foundation 
(EGPAF), Liverpool Voluntary Counselling and Testing (LVCT), African Medical and Research Foundation 
(AMREF), World Bank, and Global Fund. This publication was made possible by support from the US President’s 
Emergency Plan for AIDS Relief through cooperative agreements (#PS001805, GH000069, and PS001814) from 
the US Centers for Disease Control and Prevention, Division of Global HIV/AIDS. This work was also funded in 
part by support from the Global Fund, World Bank, and the Joint United Nations Team for HIV/AIDS.
The authors would like to thank George Rutherford and Rennatus Mdodo for reviewing and providing input on the 
manuscript and the KAIS Study Group for their contribution to the design of the survey and collection of the data 
set: Willis Akhwale, Sehin Birhanu, John Bore, Angela Broad, Robert Buluma, Thomas Gachuki, Jennifer 
Galbraith, Anthony Gichangi, Beth Gikonyo, Margaret Gitau, Joshua Gitonga, Mike Grasso, Malayah Harper, 
Andrew Imbwaga, Muthoni Junghae, Mutua Kakinyi, Samuel Mwangi Kamiru, Nicholas Owenje Kandege, Lucy 
Odhiambo et al. Page 7













Kanyara, Yasuyo Kawa-mura, Timothy Kellogg, George Kichamu, Andrea Kim, Lucy Kimondo, Davies Kimanga, 
Elija Kinyanjui, Stephen Kipkerich, Danson Kimutai Koske, Boniface O. K’Oyugi, Veronica Lee, Serenita Lewis, 
William Maina, Ernest Makokha, Agneta Mbithi, Joy Mirjahangir, Ibrahim Mohamed, Rex Mpazanje, Silas Mulwa, 
Nicolas Muraguri, Patrick Murithi, Lilly Muthoni, James Muttunga, Jane Mwangi, Mary Mwangi, Sophie 
Mwanyumba, Francis Ndichu, Anne Ng’ang’a, James Ng’ang’a, John Gitahi Ng’ang’a, Lucy Ng’ang’a, Carol 
Ngare, Bernadette Ng’eno, Inviolata Njeri, David Njogu, Bernard Obasi, Macdonald Obudho, Edwin Ochieng, 
Linus Odawo, Jacob Odhiambo, Caleb Ogada, Samuel Ogola, David Ojakaa, James Kwach Ojwang, George 
Okumu, Patricia Oluoch, Tom Oluoch, Kenneth Ochieng Omondi, Osborn Otieno, Yakubu Owolabi, Bharat 
Parekh, George Rutherford, Sandra Schwarcz, Shahnaaz Sharrif, Victor Ssempijja, Lydia Tabuke, Yuko Takenaka, 
Mamo Umuro, Brian Eugene Wakhutu, Wanjiru Waruiru, Celia Wandera, John Wanyungu, Anthony Waruru, Paul 
Waweru, Larry Westerman, and Kelly Winter.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report. UNAIDS Report on the 
Global AIDS Epidemic 2013. Geneva, Switzerland: UNAIDS; 2013. 
2. Severe P, Juste M, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected 
adults in Haiti. N Engl J Med. 2010; 363:257–265. [PubMed: 20647201] 
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral 
therapy. N Engl J Med. 2011; 365:493–505. [PubMed: 21767103] 
4. The HIV-Causal Collaboration. The effect of combined antiretroviral therapy on the overall 
mortality of HIV-infected individuals. AIDS. 2010; 24:123–137. [PubMed: 19770621] 
5. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual 
transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010; 340:c2205. 
[PubMed: 20472675] 
6. Donnell D, Kiarie J, Thomas J, et al. Heterosexual HIV-1 transmission after initiation of 
antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375:2092–2098. Available at: 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60705-2/abstract. [PubMed: 
20537376] 
7. Kimanga DO, Ogola S, Umuro A, et al. Prevalence and incidence of HIV infection, trends, and risk 
factors among persons aged 15–64 years in Kenya: results from a nationally representative study. J 
Acquir Immune Defic Syndr. 2014; 66(suppl 1):S13–S26. [PubMed: 24445338] 
8. National HIV/AIDS Control Programme (NASCOP). 2007 Kenya AIDS Indicator Survey Final 
Report. Nairobi, Kenya: NASCOP; 2009. Available at: http://nascop.or.ke/library/3d/
KAIS_2007_Final.pdf [Accessed August 1, 2013]
9. National AIDS and STI Control Programme (NASCOP). Guidelines for Antiretroviral Therapy in 
Kenya. 4. Nairobi, Kenya: NASCOP; 2011. Available at: http://nascop.or.ke/library/ART
%20guidelines/Guidelines%20for%20Antiretroviral%20Drug%20Therapy%20in%20Kenya.pdf 
[Accessed July 7, 2013]
10. National AIDS Control Council (NACC). Kenya National AIDS Strategic Plan 2009/10 – 2012/13: 
Delivering on Universal Access to Services. Nairobi, Kenya: NAAC; 2009. Available at: http://
www.nacc.or.ke/nacc%20downloads/knasp_iii.pdf [Accessed July 7, 2013]
11. Ng’ang’a A, Waruiru W, Ngare G, et al. Status of HIV testing and counselling in Kenya: results 
from a nationally representative population-based survey. J Acquir Immune Defic Syndr. 2014; 
66(suppl 1):S27–S36. [PubMed: 24732818] 
12. Office of Global AIDS Coordinator (OGAC). Kenya Annual Progress Report 2012. Washington, 
DC: OGAC; 2012. 
13. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection, 2013. Geneva, Switzerland: WHO; 2013. Available at: 
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf [Accessed October 8, 
2013]
14. Waruiru W, Kim AA, Kimanga DO, et al. The Kenya AIDS indicator survey 2012: rationale, 
methods, description of participants and response rates. J Acquir Immune Defic Syndr. 2014; 
66(suppl 1):S3–S12. [PubMed: 24732819] 
15. Kenya National Bureau of Statistics (KNBS). 2009 Kenya population and housing census results: 
population distribution by age, sex and administrative units. Nairobi, Kenya: KNBS; 2010. 
Odhiambo et al. Page 8













Available at: http://www.knbs.or.ke/docs/PresentationbyMinisterforPlanningrevised.pdf [Accessed 
August 1, 2013]
16. Katz IT, Bassett IV, Wright AA. PEPFAR in transition—implications for HIV care in South 
Africa. N Engl J Med. 2013; 369:1385–1387. [PubMed: 24106930] 
17. Marks G, Crepaz N, Janssen R. Estimating sexual transmission of HIV from persons aware and 
unaware that they are infected with the virus in the USA. AIDS. 2006; 20:1447–1450. [PubMed: 
16791020] 
18. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human 
immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342:921–929. 
[PubMed: 10738050] 
19. Sirengo M, Muthoni L, Kellogg TA, et al. Mother to child transmission of HIV in Kenya: results 
from a nationally representative study. J Acquir Immune Defic Syndr. 2014; 66(suppl 1):S66–S74. 
[PubMed: 24732822] 
20. Wafula R, Masyuko S, Nganga L, et al. Engagement in HIV care among Kenyan adults and 
adolescents: results from a national population-based survey. J Acquir Immune Defic Syndr. 2014; 
66(suppl 1):S98–S105. [PubMed: 24732825] 
21. Ingle S, May M, Uebel K, et al. Outcomes in patients waiting for anti-retroviral treatment in the 
Free State Province, South Africa: prospective linkage study. AIDS. 2010; 24:2717–2725. 
[PubMed: 20935554] 
22. Geng EH, Bwaba MB, Muyindike W, et al. Failure to initiate ART, loss to follow-up and mortality 
among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic 
Syndr. 2013; 63:e64–e71. [PubMed: 23429504] 
23. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment 
period in an antiretroviral therapy program under normal health service conditions in Uganda. 
BMC Public Health. 2009; 9:290. [PubMed: 19671185] 
24. Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care 
systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr. 
2009; 52:397–405. [PubMed: 19550350] 
Odhiambo et al. Page 9

























Odhiambo et al. Page 10
TABLE 1
Characteristics of HIV-Infected Persons, Kenya AIDS Indicator Survey 2012
Characteristic HIV Infected, Unweighted, N* (Unweighted %) Weighted % (95% CI)
Overall 648 (100) 100.0
Sex
 Men 193 (29.8) 37.9 (33.5 to 42.3)
 Women 455 (70.2) 62.1 (57.7 to 66.5)
Age group, yrs
 15–29 187 (28.9) 29.0 (25.0 to 33.1)
 30–39 205 (31.6) 30.7 (26.3 to 35.2)
 40 and above 256 (39.5) 40.2 (36.4 to 44.1)
Highest educational attainment
 Primary or less 312 (48.1) 45.6 (40.9 to 50.2)
 Secondary/vocational 158 (24.4) 25.4 (21.1 to 29.7)
 Post-secondary 177 (27.3) 29.1 (24.2 to 33.9)
Marital status
 Married/cohabiting 385 (59.4) 61.1 (56.1 to 66.2)
 Ever widowed 106 (16.4) 15.4 (11.9 to 18.9)
 Other 157 (24.2) 23.5 (19.5 to 27.4)
Region
 Nairobi 67 (10.3) 9.6 (7.0 to 12.2)
 Central 60 (9.3) 8.8 (6.2 to 11.4)
 Coast 66 (10.2) 6.9 (4.8 to 9.1)
 Eastern 75 (11.6) 10.1 (6.4 to 13.7)
 Nyanza 242 (37.3) 37.7 (30.8 to 44.5)
 Rift Valley 79 (12.2) 17.6 (12.8 to 22.4)
 Western 59 (9.1) 9.2 (5.3 to 13.2)
Residence
 Rural 373 (57.6) 56.8 (50.4 to 63.2)
 Urban 275 (42.4) 43.2 (36.8 to 49.6)
Wealth index
 Poorest 97 (15.0) 14.2 (10.5 to 17.9)
 Second 153 (23.6) 24.2 (18.9 to 29.6)
 Middle 137 (21.1) 21.2 (16.8 to 25.6)
 Fourth 159 (24.5) 23.5 (18.7 to 28.2)
 Richest 102 (15.7) 16.9 (12.8 to 21.0)
*
Due to missing responses, totals vary between variables.
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